08 Nov 2022 by admin in UncategorizedComments Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
07 Nov 2022 by admin in UncategorizedComments Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
03 Nov 2022 by admin in UncategorizedComments NextCure Provides Update and Reports Third Quarter 2022 Financial Results
03 Nov 2022 by admin in UncategorizedComments Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
03 Nov 2022 by admin in UncategorizedComments Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
27 Oct 2022 by admin in UncategorizedComments NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
17 Oct 2022 by admin in UncategorizedComments Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
03 Oct 2022 by admin in UncategorizedComments Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA)
